U.S. markets closed
  • S&P Futures

    3,838.75
    +10.75 (+0.28%)
     
  • Dow Futures

    31,429.00
    +58.00 (+0.18%)
     
  • Nasdaq Futures

    12,822.25
    -9.50 (-0.07%)
     
  • Russell 2000 Futures

    2,193.00
    -7.00 (-0.32%)
     
  • Crude Oil

    63.24
    -0.29 (-0.46%)
     
  • Gold

    1,769.20
    -6.20 (-0.35%)
     
  • Silver

    27.38
    -0.31 (-1.10%)
     
  • EUR/USD

    1.2183
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.4019
    +0.0006 (+0.04%)
     
  • USD/JPY

    105.9610
    -0.2690 (-0.25%)
     
  • BTC-USD

    47,314.79
    -3,409.82 (-6.72%)
     
  • CMC Crypto 200

    942.71
    -51.95 (-5.22%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,412.15
    -756.12 (-2.51%)
     

AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference being held virtually.

AtriCure’s management is scheduled to present on Monday, September 14, 2020, at 2:15 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005362/en/

Contacts

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com

Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
lynn@gilmartinir.com